Treatment and prognosis of solid and cystic brain metastases | CMAR - Dove Medical Press
Introduction Lung cancer is the most common cause of cancer death throughout the world. 1 Brain metastasis (BM), the most common intracranial tumor, manifests in 10–20% of patients with non-small cell lung cancer (NSCLC) at diagnosis. 2,3 Approximately 30–50% of patients with NSCLC develop BM during their disease course. 4 Patients with BM commonly have poor prognosis, and untreated patients have a median survival of just 1–2 months. 5 Whole brain radiotherapy (WBRT) increases the median survival to 4–6 months. 6 The development of treatments for BM, including surgery, WBRT, stereotactic radiotherapy, chemotherapy and targeted therapy, has greatly extended the survival of patients with BM. 7 Stereotactic radiosurgery (SRS) is a new treatment method applied in select conditions of relatively oligometastasis (five or fewer BMs). 8 Cystic BM is uncommon, and cystic brain lesions are often deemed unsuitable for radiation, because of cystic lesions' insensitivity to radiothera...